Daily Stock Opinions and Ratings

Opinions

Bill Carrigan Neurochem NRM-T DON'T BUY Apr 27, 2005

Looking at his relative performer chart, it's been an underperformer. Has negative money flow. In a very clear downtrend.

Bill Carrigan

Unlock Rating

$9.160

Stock price when the opinion was issued

biotechnology pharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

BUY

Has a very strong range of products.

TOP PICK

Into phase 3 trial. All cashed up. Will start to be getting attention.

PAST TOP PICK

(A top pick Sept 9/03. Up 58%.) As a potential treatment for Alzheimer's. Good technology. Has some US financing which will get US investors interested.

PAST TOP PICK

(A top pick Sept 9/03. Up100 %.) Still likes. The market opportunity is so big, would still buy at this price.

BUY

Has been moving sideways which, for a biotech, is not too bad. The company has good backing. Should see considerable upside.

DON'T BUY

Feels it's a little pricey at these levels given where they are in the development of their program. Have some interesting programs.

BUY

There has been a general selloff of biotech stocks. Still believe in this company.

SELL

He likes it, the only downside is that because the Japaneese market has risen 40% over the last year, it's a bit expensive right now. He suggests going to a different fund which is not so centered on the Japaneese market.

COMMENT

The name of the company was indistinct and this is the closest result in the data base. It is a biotech company focused on brain health. It acquired an AI company called Metro Mark. It is signing more and more deals with pharmaceutical companies for up-front and royalty payments.

Most Recent Experts

Stockchase Insights

5i Research

Michael Hakes - CFA, MBA

Murray Wealth Group

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jim Lebenthal

Cerity Partners

Brenda Vingiello, CIO, Sand Hill Global Advisors

Sand Hill Global Advisors

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Bill Carrigan Neurochem NRM-T DON'T BUY Apr 27, 2005

You might be interested:

Neurochem(NRM-T)

Neurochem(NRM-T)

Neurochem(NRM-T)

Neurochem(NRM-T)

Neurochem(NRM-T)

Neurochem(NRM-T)

Neurochem(NRM-T)

Neurochem(NRM-T)

Neurochem(NRM-T)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Stockchase Insights

Michael Hakes - CFA, MBA

Stephen Weiss, Founder, Short Hills Capital Partners

Jim Lebenthal

Brenda Vingiello, CIO, Sand Hill Global Advisors